

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4683326

| | | |
|---|-----------------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | ASSIGNMENT | |
| CONVEYING PARTY DATA | | |
| | Name | Execution Date |
| | SANTARIS PHARMA A/S | 03/22/2007 |
| RECEIVING PARTY DATA | | |
| Name: | ENZON PHARMACEUTICALS, INC. | |
| Street Address: | 685 ROUTE 202/206 | |
| City: | BRIDGEWATER | |
| State/Country: | NEW JERSEY | |
| Postal Code: | 08807 | |
| PROPERTY NUMBERS Total: 1 | | |
| | Property Type | Number |
| | Application Number: | 15243646 |
| CORRESPONDENCE DATA | | |
| Fax Number: | (801)578-6999 | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | |
| Phone: | 8013283131 | |
| Email: | loren.hulse@stoel.com | |
| Correspondent Name: | LOREN R. HULSE | |
| Address Line 1: | 201 SOUTH MAIN STREET | |
| Address Line 2: | STE. 1100 | |
| Address Line 4: | SALT LAKE CITY, UTAH 84111 | |
| ATTORNEY DOCKET NUMBER: | 48188/5204 | |
| NAME OF SUBMITTER: | LOREN R. HULSE | |
| SIGNATURE: | /LOREN R. HULSE/ | |
| DATE SIGNED: | 11/10/2017 | |
| Total Attachments: 1 | | |
| source=2AssignmentSantaristoenzonPharm#page1.tif | | |

SANTARIS PHARMA

ASSIGNMENT

WHEREAS the UNDERSIGNED, is an authorized officer of SANTARIS PHARMA A/S, a Danish Corporation having a principal place of business at Bøge Allé 3, DK-2970, Hørsholm, Denmark (SANTARIS) and whereas SANTARIS is the assignee of the entire worldwide right, title and interest in certain new and useful improvements (INVENTION) disclosed, shown, and described in an APPLICATION for Letters Patent of the United States of America entitled:

"POTENT LNA OLIGONUCLEOTIDES FOR INHIBITION OF HIF-1A EXPRESSION"

Said APPLICATION being identified as U.S. patent application serial no. 11/271,686, filed on November 9, 2005 and having an assignment recorded at Reel 018088 and Frame 0007 on July 6, 2006;

WHEREAS, ENZON PHARMACEUTICALS, INC., a Delaware Corporation having a principal place of business at 685 Route 202/206, Bridgewater, NJ 08807 (ENZON) is desirous of acquiring a one half undivided interest in and to the APPLICATION in the United States which may be granted embracing the INVENTION.

NOW, THEREFORE, for and in consideration of One Dollar (\$1.00) and for other good and valuable consideration, receipt of which is hereby acknowledged, SANTARIS assigns to ENZON, its successors and assigns a one half undivided interest for the United States, in and to the INVENTION, and in and to the APPLICATIONS for Letters Patent which have been or may be filed in the United States of America on said INVENTION, and in and to any and all priority rights generated by the filing of said APPLICATION in the United States of America, which may be granted covering the INVENTION, including any continuations, continuations-in-part, substitutions, divisions, reissues or renewals thereof, said Letters Patent in the United States of America.

SANTARIS shall, upon written request of ENZON and at ENZON's expense, give such assistance as ENZON may reasonably request to enable ENZON to (a) obtain Letters Patent, in the United States of America, on said INVENTION, (b) establish, maintain and secure title in said assignee, its successors and assigns, to said INVENTION, APPLICATION and Letters Patent, including making such title of lawful public record, and (c) perform such other acts as are necessary to give full force and effect to this assignment.

IN WITNESS WHEREOF this assignment has been executed by SANTARIS on the date opposite his name.

SANTARIS PHARMA A/S

DATE

April 22, 2007


Name: Keith McCullagh
Title: C.E.O.

Santaris Ref.: 1025US